Last reviewed · How we verify

cisplatin and paclitaxel — Competitive Intelligence Brief

cisplatin and paclitaxel (cisplatin and paclitaxel) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapy, Taxane. Area: Oncology.

phase 3 Platinum-based chemotherapy, Taxane Oncology Small molecule Live · refreshed every 30 min

Target snapshot

cisplatin and paclitaxel (cisplatin and paclitaxel) — Henan Cancer Hospital. Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription, while paclitaxel stabilizes microtubules, preventing cell division.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
cisplatin and paclitaxel TARGET cisplatin and paclitaxel Henan Cancer Hospital phase 3 Platinum-based chemotherapy, Taxane

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapy, Taxane class)

  1. Henan Cancer Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cisplatin and paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/cisplatin-and-paclitaxel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: